Reported about 14 hours ago
Jaguar Health, Inc. (NASDAQ:JAGX) has completed a private placement deal on September 9, 2025, raising $2.38 million through the issuance of approximately 951 shares of Series N Perpetual Preferred Stock. The funds will be used for working capital, corporate purposes, and repayment of existing debts. The company, which specializes in plant-based pharmaceuticals for gastrointestinal issues, is also advancing its product portfolio through trials for patients with short bowel syndrome and intestinal failure, with results expected in 2026.
Source: YAHOO